SCHEMBL3390170

SCHEMBL3390170

Cc1c(C(=O)N[C@H]2CCCc3ccccc32)cnn1-c1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SPR P35270 2/20 0.68
TAS1R3 Q7RTX0 6/20 0.61
TAS1R1 Q7RTX1 6/20 0.61
TAS1R2 Q8TE23 6/20 0.61
ALDH1A1 P00352 2/20 0.57
HSD17B10 Q99714 1/20 0.57
HTT P42858 2/20 0.57
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
DHODH Q02127 1/20 0.55
LMNA P02545 2/20 0.54
PDE2A O00408 1/20 0.54
NTRK1 P04629 1/20 0.54
TSHR P16473 1/20 0.53
USP2 O75604 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C19 P33261 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3394457 1.00 SPR (0.68) SPRTAS1R3TAS1R1TAS1R2ALDH1A1
SCHEMBL2079211 0.94 SPR (0.67) SPRTAS1R3TAS1R1TAS1R2ALDH1A1
SCHEMBL3395175 0.90 SPR (0.62) SPRTAS1R3TAS1R1TAS1R2ALDH1A1
SCHEMBL3392887 0.90 SPR (0.62) SPRTAS1R3TAS1R1TAS1R2ALDH1A1
SCHEMBL18702338 0.81 SPR (1.00) SPR
SCHEMBL2854511 0.79 SPR (0.64) SPRMEN1KMT2A
SCHEMBL2854682 0.79 ALDH1A1 (0.60) SPRTAS1R3TAS1R1TAS1R2ALDH1A1
SCHEMBL2079208 0.78 RAB9A (0.57) LMNA
SCHEMBL2857348 0.78 SPR (0.54) SPRTAS1R3TAS1R1TAS1R2ALDH1A1
SCHEMBL3394452 0.78 RAB9A (0.52)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1370530-B1 ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL SANOFI AVENTIS DEUTSCHLAND (DE) 2010-12-29 EP disclosed
US-6949556-B2 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-09-27 US disclosed
US-20030022935-A1 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2003-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022935-A1 Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents VEGFA, EDNRA, NR1H2 SPR 4091/4885TAS1R3 2306/4885TAS1R1 1843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.